MDM2 inhibitor, preparation method therefor, pharmaceutical composition thereof and use thereof

A compound according to Formula I:

• or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, hydrates or solvates thereof,
• wherein,
• is selected from the group consisting of 5, 6 or 7 membered heterocyclic with 1-3 N and 0-2 heteroatoms selected from S and O;
• X is independently C═O or S═(O)2;
• n is 1, 2, 3 or 4;
• each R is selected independently from the group consisting of H, Cyano, halogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-10 membered heteroaryl with 1-3 heteroatoms selected from N, S and O;
• Z1 is selected from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkoxy, substituted or unsubstituted C3-C8 cycloalkyl(including single, fused or bridged ring form), substituted or unsubstituted C6-C10 aryl;
• Q is selected from the group consisting of
• M and p are selected independently from the group consisting of 1, 2, 3 or 4;
• Each Z2 and Z3 is selected independently from the group consisting of none, substituted or unsubstituted C1-C7 alkylidene, NR1, O, S, C═O, S═(O)2;
• Z4 is selected
• wherein, R1 is selected from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C6-C10 aryl, CN, —C(═O)—NRdRe, —C(═O)-substituted or unsubstituted C1-C6 alkoxy, —C(═O)-substituted or unsubstituted C1-C6 alkyl, —C(═O)-substituted or unsubstituted C3-C10 cycloalkyl, —C(═O)-substituted or unsubstituted C2-C6 alkenyl, —C(═O)-substituted or unsubstituted C2-C6 alkynyl;
• Rd and Re are selected independently from the group consisting of H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C6-C10 aryl;
• the Rd and Re herein form a 4-10 membered heterocyclic with adjacent N, and the heterocyclic contains 1-2 N and 0-2 S or O;
• R2 is selected from the group consisting of substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted C6-C10 aryl, substituted or unsubstituted 5-10 membered heteroaryl with 1-3 heteroatoms selected from N, S and O;
• Unless otherwise specified, “substituted” refers to being substituted by one or more (for example, 2, 3, 4, etc.) substituents selected from the group consisting of halogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C8 cycloalkyl, halogenated C3-C8 cycloalkyl, oxo, —CN, hydroxy, —NH2, carboxy, unsubstituted or substituted group selected from the group consisting of C6-C10 aryl, halogenated C6-C10 aryl, 5-10 membered heteroaryl with 1-3 heteroatoms selected from N, S and O;
• halogenated 5-10 membered heteroaryl with 1-3 heteroatoms selected from N, S and O;
• and the substituted is substituted by substituents selected from the group consisting of halogen, C1-C6 alkoxy;
• with the proviso that when Z4 is
• R, then Q is